RESEARCH PAPER
Year : 2011 | Volume
: 2 | Issue : 3 | Page : 150--157
Rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease: A comparative study of efficacy and safety
Rituparna Maiti1, Jyothirmai Jaida1, PL John Israel2, Narendar Koyagura1, Sruthi Mukkisa1, Anuradha Palani1
1 Department of Pharmacology, Prathima Institute of Medical Sciences, Nagunur Road, Karimnagar, Andhra Pradesh, India
2 Department of General Medicine, Prathima Institute of Medical Sciences, Nagunur Road, Karimnagar, Andhra Pradesh, India
Correspondence Address:
Rituparna Maiti
Department of Pharmacology, Prathima Institute of Medical Sciences, Nagunur Road, Karimnagar, Andhra Pradesh
India
Objective: To compare the efficacy and safety of rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease (GERD). Materials and Methods: A randomized, single-blinded, outdoor-based clinical study was conducted on 60 patients of mild-to-moderate erosive GERD. After baseline clinical assessment and investigations, rabeprazole (40 mg) was prescribed to 30 patients and esomeprazole (40 mg) to another 30 patients for 4 weeks. The efficacy variables were change in GERD symptom scoring, endoscopic findings, and Quality of Life in Reflux and Dyspepsia (QOLRAD) scoring over 4 weeks. Result: Heartburn, acid regurgitation, and overall GERD symptom scoring (P = 0.01) were significantly decreased with rabeprazole in comparison to esomeprazole. The comparative study of all five domains of the QOLARD questionnaire including overall scoring revealed a statistically significant improvement in the rabeprazole group. Endoscopic findings in the rabeprazole group showed an absolute improvement of 30% and relative improvement of 55% over esomeprazole. Both the drugs were well tolerated having no significant difference in the incidence of adverse effects. Conclusion: Rabeprazole (40 mg) is a better choice for mild-to-moderate GERD compared with esomeprazole (40 mg) because of its better efficacy and safety profile.
How to cite this article:
Maiti R, Jaida J, John Israel P L, Koyagura N, Mukkisa S, Palani A. Rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease: A comparative study of efficacy and safety.J Pharmacol Pharmacother 2011;2:150-157
|
How to cite this URL:
Maiti R, Jaida J, John Israel P L, Koyagura N, Mukkisa S, Palani A. Rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease: A comparative study of efficacy and safety. J Pharmacol Pharmacother [serial online] 2011 [cited 2021 Sep 28 ];2:150-157
Available from: http://www.jpharmacol.com/article.asp?issn=0976-500X;year=2011;volume=2;issue=3;spage=150;epage=157;aulast=Maiti;type=0 |
|
|
|
